Skip to main content

Fetal Lymphatic Dysplasia Targeted RASopathy Gene Panel Sequencing: Molecular Findings and Genotype-Phenotype Correlations

In brief

RASopathy gene variants found in 7 of 20 fetuses with lymphatic findings

Targeted testing found RASopathy-related variants in 7 of 20 fetuses with increased nuchal measurements or cystic hygroma despite normal chromosome tests. Three were classified as pathogenic and four as uncertain, so the 35% finding rate does not mean all seven had a confirmed diagnosis; the small study leaves the panel's broader diagnostic value to be established.

Journal
Fetal diagnosis and therapy (Q2)
Published
9 November 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Lale Yilmaz Celik, Esra Tug, Gulsum Kayhan, Meral- Yirmibes Karaoguz
PMID
43002388
DOI
10.1159/fdt/acuag030

Why clinicians should know about it

  • Picked for Embryology (top studies of the week, 15 November 2026): Prenatal genetics links lymphatic malformations with RASopathy variants

Abstract

INTRODUCTION: Prenatal diagnosis of lymphatic dysplasia (LD) remains difficult, especially in fetuses with normal karyotype and chromosomal microarray (CMA) results. This retrospective and prospective study (2022-2023) aimed to evaluate the contribution of RASopathy-associated gene analysis, as an advanced molecular test, to the etiology of pregnancies undergoing invasive testing for increased NT/NF and/or cystic hygroma when conventional cytogenetic and molecular karyotyping were normal. METHODS: Twenty fetuses with ultrasound findings including cystic hygroma, increased nuchal translucency (NT ≥3.5 mm), and/or increased nuchal fold (NF ≥6 mm) were enrolled after normal karyotype and CMA analyses. DNA obtained from chorionic villus sampling or amniocentesis was analyzed using targeted next-generation sequencing of RASopathy-associated genes. Variants were interpreted according to ACMG/ACGS guidelines. RESULTS: RASopathy-related variants were identified in 7 of 20 fetuses (35%). Pathogenic variants were detected in the HRAS, PTPN11, and RIT1 genes, while variants of uncertain significance were found in the MAP2K1, RAF1, MAP2K2, and SPRED1 genes. In cases with parental testing, pathogenic variants were confirmed as de novo. No clinically significant variants were identified in the remaining fetuses. CONCLUSION: These findings demonstrate that a considerable proportion of fetuses with idiopathic LD harbor RASopathy-related variants. Incorporating targeted RASopathy panels into prenatal evaluation may improve diagnosis, counseling, pregnancy management, and assessment of recurrence risk.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.